Zeria Of Japan To Buy Tilotts Of Switzerland For $128 Million
This article was originally published in PharmAsia News
Japan's Zeria Pharma said it plans to buy Tilotts Pharma of Switzerland for just over $128 million. Zeria reportedly made the purchase to expand its drug pipeline and widen its marketing ability abroad. Tilotts is attractive to Zeria because of its Asacol (mesalamine) drug for treating hypersensitive bowel syndrome. The product is considered a good fit with Zeria's gastrointestinal line of drugs. Zeria has been developing and marketing Asacol in Japan for the past five years. The purchase of Tilotts gives the Japanese company rights to sell the drug in 53 countries. (Click here for more - a subscription may be required
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.